Please login to the form below

Not currently logged in
Email:
Password:

pricing model

This page shows the latest pricing model news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • New trial results suggest CAR-T effects are durable in lymphoma New trial results suggest CAR-T effects are durable in lymphoma

    Ultimately, the winning player could be the company that gets the pricing and access model just right and keeps the cost not insignificant production costs of CAR-T under close control.

  • Daily Brief Daily Brief

    A major new study published in Nature Reviews calls for a ‘global revolution’in the pricing of new cancer drugs – and claims an algorithm could turn what some see as the ... The paper, titled Sustainability and affordability of cancer drugs: a

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    These delays are worsened for diseases as there is often limited evidence available to meet the requirements for access and pricing decisions.”. ... The hope is that the model could also be used for other rare diseases and provide greater certainty

  • Post-Shkreli KaloBios pledges transparent pricing Post-Shkreli KaloBios pledges transparent pricing

    The new pricing model "will guide the company's strategy and operations", according to new CEO Cameron Durrant, who has pledged to price its Chagas disease treatment benznidazole on the basis ... Our new pricing model is a commitment to define and

  • UK pharma's contribution to NHS hits £1bn mark UK pharma's contribution to NHS hits £1bn mark

    The AAR was announced by Minister for Life Sciences George Freeman in November 2014 after it became apparent that plans to replace the PPRS with a value-based pricing model - along

More from news
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Brexit and Trump Brexit and Trump

    that we need to return to servicing a high-volume, low-cost model in consumer healthcare, and a parity pricing model in Rx.

  • Pharma deals in September 2015 Pharma deals in September 2015

    to pursue a “ robust” pricing model. ... Pharmaceuticals. He has also written a letter to employees to assuage their concerns over company's business model, potential exposure and the fall in the company's stock price (it fell

  • Interview: Richard Bergström, EFPIA Interview: Richard Bergström, EFPIA

    These are good examples of where legislation helps promote innovation, but unfortunately it's the access to markets, pricing and reimbursement that are deteriorating. ... I have worked very closely with the Swedish government to shape value-based-pricing.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • A roadmap to strategic drug pricing

    A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... Pharma firms must identify products that will benefit from innovative pricing models, and then forge the types

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics